PCI Pharma Services, a Philadelphia, Pennsylvania-based pharmaceutical contract service provider, has acquired PPP, a Melbourne, Victoria, Australia-headquartered provider of clinical trial manufacturing, packaging, storage, and distribution services.

PPP has a suite of services, including early clinical-phase sterile and non-sterile drug manufacture of investigational medicines, packaging, and labeling services for investigational products as well as logistical services, including storage and distribution to global investigational sites. PPP’s experience supports projects across a range of temperature conditions, including controlled-room temperature; 2 degrees – 8 degrees C;  -20 degrees C;  and -80 degrees C environments, which expands PCI’s existing capabilities in storing, packaging, and shipping cold-chain products. PPP is currently undertaking a facility expansion and upgrade to add additional storage and distribution services, labeling, and packaging rooms, Grade D manufacturing as well as sterile-fill manufacturing capabilities for Phase II clinical studies.

PCI says PPP’s suite of services adds to its global portfolio of clinical and commercial services, including clinical- and commercial-scale drug manufacturing, packaging, and labeling of clinical-trial medicines, global logistical services to investigational sites, and commercial contract packaging services.

In October 2017, PCI announced the acquisition of Millmount Healthcare, a pharmaceutical and healthcare contract packaging services provider in Dublin, Ireland. The move added four Dublin-based facilities to PCI’s global supply network.

In addition to acquisitions, PCI says it has been investing in its core business through a number of investments and site expansions. PCI announced cold-chain and ultra cold-chain expansions at its US-based Philadelphia and Rockford, Illinois locations in support of temperature-controlled packaging, storage, and distribution. PCI says it has also undertaken site expansions of its Tredegar and Bridgend facilities in the UK. The company says new packaging lines have been installed in its commercial packaging business, and it has expanded its global capacity in serialization and anticounterfeiting technologies.

Source: PCI Pharma Services